Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 237

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 237
---
 tax assets. Management considers projected future taxable income, the scheduled reversal of deferred tax assets, and tax planning strategies in making this assessment. The amount of the deferred tax asset considered realizable could change materially in future periods.
 

4.             Recent         
     accounting pronouncements
------------------------------
 
New standards and amendments
 
The Company applied for the first-time certain standards and amendments, which are effective for annual periods beginning on or after January 1, 2024 (unless otherwise stated). The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
 
The adoption of these new or amended standards did not result in substantial changes to the Company’s accounting policies and has no material effect on the amounts reported for the current of prior financial years.
 
Amendments to IAS 1 - Classification of Liabilities as Current or Non-current
 
The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:
 

●                                             What                                          
                            is meant by a right to defer settlement                         
--------------------------------------------------------------------------------------------
●   That                                                                                    
    a right to defer must exist at the end of the reporting period                          
●   That                                                                                    
    classification is unaffected by the likelihood that an entity will exercise its deferral
    right                                                                                   
●   That                                                                                    
    only if an embedded derivative in a convertible liability is itself an equity instrument
    would the terms of a liability not impact its classification                            
 
In addition, an entity is required to disclose when a liability arising from a loan agreement is classified as non-current and the entity’s right to defer settlement is contingent on compliance with future covenants within twelve months. The amendments have not had an impact on the classification of the Company’s liabilities.
 
New standards and interpretations not yet adopted
 
Certain amendments to accounting standards have been published that are not mandatory for December 31, 2024 reporting periods and have not been early adopted by the Company. The Company is currently assessing the impact these new accounting standards and amendments may have on the Company’s financial statements. These new standards and amendments include:
 

●                                            Amendments                                         
        to the Classification and Measurement of Financial Instruments – Amendments to IFRS     
    9 and IFRS 7 - effective for annual reporting periods beginning on or after January 1, 2026.
------------------------------------------------------------------------------------------------
●   IFRS                                                                                        
    18 Presentation and Disclosures in Financial Statements - effective for annual reporting    
    periods beginning on or after January 1